Skip to main content
SpringerLink
Log in

Design and Implementation of High-Throughput Screening Assays

  • Protocol
  • First Online:
High Throughput Screening

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1439))

Abstract

HTS remains at the core of the drug discovery process, and so it is critical to design and implement HTS assays in a comprehensive fashion involving scientists from the disciplines of biology, chemistry, engineering, and informatics. This requires careful consideration of many options and variables, starting with the choice of screening strategy and ending with the discovery of lead compounds. At every step in this process, there are decisions to be made that can greatly impact the outcome of the HTS effort, to the point of making it a success or a failure. Although specific guidelines should be established to ensure that the screening assay reaches an acceptable level of quality, many choices require pragmatism and the ability to compromise opposing forces.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Macarrón R, Banks MN, Bojanic D et al. (2011) Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov 10:188–195

    Article  Google Scholar 

  2. Wassermann AM, Camargo LM, Auld DS (2014) Composition and applications of focus libraries to phenotypic assays. Front Pharmacol 5:1–12

    Article  Google Scholar 

  3. Horman SR, Hogan C, Delos Reyes C, Lo F, Antzcak C (2015) Challenges and opportunities towards enabling phenotypic screening of complex and 3D cell models. Future Med Chem 7(4):513–525

    Article  CAS  Google Scholar 

  4. Shalem O, Sanjana NE, Hartenian E et al. (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343(6166):84–87

    Article  CAS  Google Scholar 

  5. Nicodeme E, Jeffrey KL, Shaefer U et al. (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468:1119–1123

    Article  CAS  Google Scholar 

  6. Comley J (2014) HTS Metrics and future directions trends 2014. http://www.htstec.com/consultancyitem.aspx?Item=408

  7. Drewry D, Macarrón R (2010) Enhancements of screening collections to address areas of unmet medical need: an industry perspective. Curr Opin Chem Biol 14:289–298

    Article  CAS  Google Scholar 

  8. Macarrón R (2006) Critical review of the role of HTS in drug discovery. Drug Discov Today 11:277–279

    Article  Google Scholar 

  9. Shoichet BK (2006) Screening in a spirit haunted world. Drug Discov Today 11:607–615

    Article  CAS  Google Scholar 

  10. Baell J, Holloway G (2010) New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 53:2719–2740

    Article  CAS  Google Scholar 

  11. Inglese J, Johnson RL, Simeonov A et al. (2007) High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 3:466–479

    Article  CAS  Google Scholar 

  12. Wigle T, Herold JM, Senisterra GA et al. (2010) Screening for inhibitors of low-affinity epigenetic peptide-protein interactions. J Biomol Screen 15(1):62–71

    Article  CAS  Google Scholar 

  13. Debad JD, Glezer EN, Wohlstadter JN, Sigal GB (2004) Clinical and biological applications of ECL. In: Bard AJ (ed) Electrogenerated chemiluminescence. Marcel Dekker, New York, pp 43–78

    Google Scholar 

  14. Lowe DM, Gee M, Hasmam C et al. (2014) Lead discovery for human kynurenine 3-monooxygenase by high-throughput rapidfire mass spectrometry. J Biomol Screen 19:508–515

    Article  Google Scholar 

  15. Schroeder KS, Neagle BD (1996) FLIPR: a new instrument for accurate, high throughput optical screening. J Biomol Screen 1:75–80

    Article  CAS  Google Scholar 

  16. Thomsen W, Frazer J, Unett D (2005) Functional assays for screening GPCR targets. Curr Opin Biotechnol 16:655–665

    CAS  Google Scholar 

  17. Farre C, Fertig N (2012) HTS techniques for patch clamp-based ion channel screening—advances and economy. Expert Opin Drug Discov 7(6):515–524

    Article  CAS  Google Scholar 

  18. Fan F, Wood KV (2005) Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol 5:127–136

    Article  Google Scholar 

  19. Assay Guidance Manual Version 4.1 (2005) Eli Lilly and Company and NIH Chemical Genomics Center. http://www.ncbi.nlm.nih.gov/books/NBK53196/. Accessed Jun 2015

  20. Cheng YC, Prussof W (1973) Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099–3108

    Article  CAS  Google Scholar 

  21. Bush K (1983) Screening and characterization of enzyme inhibitors as drug candidates. Drug Metab Rev 14:689–708

    Article  CAS  Google Scholar 

  22. Tipton KF (1980) Kinetics and enzyme inhibition studies. In: Sandler M (ed) Enzyme inhibitors as drugs. University Park Press, Baltimore, pp 1–23

    Google Scholar 

  23. Burt D (1986) Receptor binding methodology and analysis. In: O’Brien RA (ed) Receptor binding in drug research. Decker, New York, pp 4–29

    Google Scholar 

  24. Gupta S, Indelicato S, Jethwa V et al. (2007) Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 321:1–18

    Article  CAS  Google Scholar 

  25. Airenne KJ, Hu YC, Kost T et al. (2013) Baculovirus: an insect-derived vector for diverse gene transfer applications. Mol Ther 21(4):739–749

    Article  CAS  Google Scholar 

  26. Lundholt B, Scudder K, Pagliaro L (2003) A simple technique for reducing edge effect in cell-based assays. J Biomol Screen 8:566–570

    Article  CAS  Google Scholar 

  27. Lutz MW, Menius JA, Choi TD et al. (1996) Experimental design for high-throughput screening. Drug Discov Today 1:277–286

    Article  CAS  Google Scholar 

  28. Taylor P, Stewart F, Dunnington DJ et al. (2000) Automated assay optimization with integrated statistics and smart robotics. J Biomol Screen 5:213–225

    Article  CAS  Google Scholar 

  29. Zhang JH, Chung TDY, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67–73

    Article  Google Scholar 

  30. Iversen PW, Eastwood BJ, Sittampalam GS, Cox KL (2006) A comparison of assay performance measures in screening assays: signal window, Z′ factor, and assay variability ratio. J Biomol Screen 11:247–252

    Article  CAS  Google Scholar 

  31. Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R (2006) Statistical practice in high-throughput screening data analysis. Nat Biotechnol 24:167–175

    Article  CAS  Google Scholar 

  32. Gough AH, Chen N, Shun TY et al. (2014) Identifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discovery. PLoS One 9(7):1932–6203

    Article  Google Scholar 

  33. Barnett V (1974) Elements of sampling theory. The English Universities Press, London, pp 42–46

    Google Scholar 

  34. Coma I, Clark L, Diez E et al. (2009) Process validation and screen reproducibility in high-throughput screening. J Biomol Screen 14:66–76

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors are grateful to the many colleagues at GlaxoSmithKline past and present who helped over the years to shape the screening process and to build the collective knowledge succinctly described in this introduction.

Author information

Authors and Affiliations

  1. Alternative Drug Discovery, GSK Pharmaceuticals, Gunnels Wood Road, Stevenage, Herts, SG1 2NY, UK

    David J. Powell

  2. GSK Pharmaceuticals R&D, Philadelphia, PA, USA

    Robert P. Hertzberg

  3. Alternative Drug Discovery, GSK Pharmaceuticals, 1250 South Collegeville Road, Upper Providence, PA, 19426, USA

    Ricardo Macarrόn

Authors
  1. David J. Powell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert P. Hertzberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ricardo Macarrόn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David J. Powell .

Editor information

Editors and Affiliations

  1. Epizyme, Inc., Cambridge, Massachusetts, USA

    William P. Janzen

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this protocol

Cite this protocol

Powell, D.J., Hertzberg, R.P., Macarrόn, R. (2016). Design and Implementation of High-Throughput Screening Assays. In: Janzen, W. (eds) High Throughput Screening. Methods in Molecular Biology, vol 1439. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3673-1_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3673-1_1

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-3671-7

  • Online ISBN: 978-1-4939-3673-1

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation